Title of article :
Lysosomal Storage Disease
Author/Authors :
GHOFRANI MD1، Mohammad نويسنده Professor of Pediatric Neurology, Pediatric Neurology Research Center, Tehran, Iran ,
Issue Information :
فصلنامه با شماره پیاپی 0 سال 2012
Abstract :
Lysosomes are cytoplasmic organelles containing hydrolytic enzymes that
degrade the macromolecules proteins of cellular catabolism. The causes of
lysosomal enzyme disorder stem from
1. Impaired enzyme synthesis
2. Abnormal enzyme targeting
3. Defect of structure of Accessory factor which is needed for enzymes
function. Clinical manifestations depend on the organ(s) involved.
Seizure disorder, mental handicap and regression are the characteristics of
many lysosomal enzyme storage diseases. The lysosomal storage disease, as
first described by Hers are characterized by an accumulation of undergraded
macromolecules within lysosomes. These disorders are clinically heterogenous
groups of inborn errors by about 50 different clinical entities. Nature of the
incompletely degraded macromolecules that accumulate in various tissues
include:
Tthe glycogen storage diseases
The mucopolysuccharidosis
The mucolipidosis
The glycoproteinosis
The sphingolipidosis
The acid lipase deficiency diseases
It is said the combined prevalence of all lysosomal storage disease is 1 in 6600
to 1 in 7700 live birth (1).
The disease entities result from various single gene mutation with each of
the enzyme defect is induced by one of the several different abnormalities.
Mutation or deletions that produce immunologically responsive or unresponsive
enzyme protein. The defect can impair glycosylation of the enzyme protein or
cause a failure to generate recognition markers that permits the enzyme to
attach itself to the lysosomal membrane. The majority of genes that encode
lysosomal various lysosomal storage disease subtypes is manifested by multi
systemic involvement. Disease manifestation may be evident prenatally or at
any time from birth to adulthood on the therapeutic front several modalities
of treatment have been suggested Enzyme replacement therapy, enzyme
enhancement therapy, substrate reduction therapy and gene therapy are the
different approaches which at present, are being tried.
Treatment of the secondary disabilities like seizure
disorder, sensory deficit, behavioral problem, and
sleep-wake cycle disorder has positive impact on the
patients quality of life and help address some of parental
anxieties. Genetic counseling of affected individuals
and their relatives is also important component of care
of the patient and family
Journal title :
Iranian Journal of Child Neurology (IJCN)
Journal title :
Iranian Journal of Child Neurology (IJCN)